Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Switch from dose-intensified IV infliximab to subcutaneous infliximab in inflammatory bowel disease
ACTRN12622001458729Phase 4Active, not recruiting
- Sponsor
- The Alfred Hospital
- Start
- Mar 2023
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 4, randomised, open-label trial of infliximab in inflammatory bowel disease (IBD), Crohn's disease and autoimmune colitis (2 arms), sponsored by The Alfred Hospital. Started Mar 2023; status: active, not recruiting.
02
Drugs
infliximab
03
Conditions
inflammatory bowel disease (IBD)Crohn's diseaseautoimmune colitis
Beyond the preview
Go deeper on ACTRN12622001458729.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ACTRN12622001458729.